Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

This study is looking at an immunotherapy treatment called V940 (mRNA-4157) with pembrolizumab to treat melanoma.

The following is a summary of "A phase 2 study of frontline pembrolizumab in follicular lymphoma," published in the October 2024 issue of Hematology by Ho et al. The tumor microenvironment (TME), ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...